London South East caught up with Bytrol (LSE:BYOT) CEO David Traynor. Byotrol is an AIM-listed healthcare company which specialises in surface and hand sanitisers, and on Thursday they announced a very positive trading update.
"We've had an extraordinary year, are pleased with the performance so far and are very excited about what's to happen in the future for us" said David Traynor.
"Turnover has pretty much doubled in 12 months to over £11 million, and EBITDA was up by 6.5 times [to £1.7M], that's a pretty good performance by any measure. And we have no debt, we paid off all our debt over the year, financially we are very very strong and we are looking for growth going forwards" explained David.
Next year: "I would expect to put out more information on product launces across B2B and B2C, I would expect to be announcing more licences and alliances as we have done before, with more focus on three areas:
1. New products and ingredients for the professional market, sometimes to create a gap in their portfolio which we spot for them
2. More direct to consumer work - we did 20% of our work direct to retailers and retailers as partners, and I think we can do better than that
3. Third area is licences and alliances across those two areas."